AR009672A1 - Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par - Google Patents
Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica parInfo
- Publication number
- AR009672A1 AR009672A1 ARP970106029A ARP970106029A AR009672A1 AR 009672 A1 AR009672 A1 AR 009672A1 AR P970106029 A ARP970106029 A AR P970106029A AR P970106029 A ARP970106029 A AR P970106029A AR 009672 A1 AR009672 A1 AR 009672A1
- Authority
- AR
- Argentina
- Prior art keywords
- naftil
- trifluorometil
- fenil
- etil
- tetrahydropyridine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 238000001757 thermogravimetry curve Methods 0.000 abstract 2
- 125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- XLORXPQTDZWKBY-UHFFFAOYSA-N Cl.FC(F)(F)C1=C(C=CC=C1)N1CCC=CC1 Chemical compound Cl.FC(F)(F)C1=C(C=CC=C1)N1CCC=CC1 XLORXPQTDZWKBY-UHFFFAOYSA-N 0.000 abstract 1
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9615904A FR2757543B1 (fr) | 1996-12-23 | 1996-12-23 | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009672A1 true AR009672A1 (es) | 2000-04-26 |
Family
ID=9499043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970106029A AR009672A1 (es) | 1996-12-23 | 1997-12-19 | Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par |
Country Status (38)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757543B1 (fr) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
| FR2782082B3 (fr) * | 1998-08-05 | 2000-09-22 | Sanofi Sa | Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose |
| US9272068B2 (en) | 2010-03-12 | 2016-03-01 | Nippon Shokubai Co., Ltd. | Process for producing water-absorbing resin |
| ES2604405T3 (es) * | 2011-04-15 | 2017-03-06 | Emcure Pharmaceuticals Limited | Un procedimiento para rilpivirina mejorado |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2531707A1 (fr) * | 1982-08-16 | 1984-02-17 | Midy Spa | Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques |
| FR2757543B1 (fr) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
-
1996
- 1996-12-23 FR FR9615904A patent/FR2757543B1/fr not_active Expired - Fee Related
-
1997
- 1997-12-19 AR ARP970106029A patent/AR009672A1/es not_active Application Discontinuation
- 1997-12-22 DZ DZ970233A patent/DZ2383A1/xx active
- 1997-12-22 HR HR970699A patent/HRP970699B1/xx not_active IP Right Cessation
- 1997-12-22 MY MYPI97006233A patent/MY118015A/en unknown
- 1997-12-23 JP JP52848198A patent/JP4499188B2/ja not_active Expired - Fee Related
- 1997-12-23 AU AU56684/98A patent/AU736697B2/en not_active Ceased
- 1997-12-23 NZ NZ336130A patent/NZ336130A/xx not_active IP Right Cessation
- 1997-12-23 WO PCT/FR1997/002393 patent/WO1998028271A1/fr active IP Right Grant
- 1997-12-23 ZA ZA9711576A patent/ZA9711576B/xx unknown
- 1997-12-23 IL IL12993897A patent/IL129938A/en not_active IP Right Cessation
- 1997-12-23 AT AT97952986T patent/ATE307802T1/de active
- 1997-12-23 BR BR9714081-3A patent/BR9714081A/pt not_active Application Discontinuation
- 1997-12-23 EG EG138397A patent/EG21567A/xx active
- 1997-12-23 CZ CZ0229299A patent/CZ296689B6/cs not_active IP Right Cessation
- 1997-12-23 EE EEP199900264A patent/EE04188B1/xx not_active IP Right Cessation
- 1997-12-23 CA CA002275596A patent/CA2275596C/en not_active Expired - Fee Related
- 1997-12-23 KR KR1019997005373A patent/KR100586670B1/ko not_active Expired - Fee Related
- 1997-12-23 IN IN3761DE1997 patent/IN186976B/en unknown
- 1997-12-23 SK SK828-99A patent/SK285088B6/sk not_active IP Right Cessation
- 1997-12-23 RS YUP-289/99A patent/RS49882B/sr unknown
- 1997-12-23 PL PL97334256A patent/PL190494B1/pl not_active IP Right Cessation
- 1997-12-23 TR TR1999/01363T patent/TR199901363T2/xx unknown
- 1997-12-23 SI SI9730720T patent/SI0950050T1/sl unknown
- 1997-12-23 DE DE69734460T patent/DE69734460T2/de not_active Expired - Lifetime
- 1997-12-23 ES ES97952986T patent/ES2251038T3/es not_active Expired - Lifetime
- 1997-12-23 RU RU99116597/04A patent/RU2192416C2/ru not_active IP Right Cessation
- 1997-12-23 HU HU0001387A patent/HU227425B1/hu not_active IP Right Cessation
- 1997-12-23 DK DK97952986T patent/DK0950050T3/da active
- 1997-12-23 CN CN97180863A patent/CN1129580C/zh not_active Expired - Fee Related
- 1997-12-23 EP EP97952986A patent/EP0950050B1/fr not_active Expired - Lifetime
- 1997-12-23 UA UA99063521A patent/UA60324C2/uk unknown
- 1997-12-23 UY UY24825A patent/UY24825A1/es not_active IP Right Cessation
- 1997-12-23 CO CO97074792A patent/CO5070688A1/es unknown
-
1998
- 1998-01-21 TW TW086119629A patent/TW518322B/zh not_active IP Right Cessation
- 1998-03-11 SA SA98180971A patent/SA98180971B1/ar unknown
-
1999
- 1999-06-10 IS IS5076A patent/IS2357B/is unknown
- 1999-06-22 NO NO19993076A patent/NO312364B1/no not_active IP Right Cessation
-
2009
- 2009-05-07 JP JP2009112971A patent/JP2009197022A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP056023A (es) | Métodos para aislar la forma cristalina I de la 5-azacitidina | |
| CO5011099A1 (es) | Formulaciones en polvo en estado cristalino estable | |
| ES2158778B1 (es) | Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. | |
| NO954400D0 (no) | Substituerte pyrrolidin-3-yl-alkyl-piperidiner som er anvendbare som tachykininantagonister | |
| ES2185307T3 (es) | Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion. | |
| GT199900119A (es) | Jarabe antihistaminico estabilizado. | |
| BRPI0313942C1 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
| ES2053508T3 (es) | Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos. | |
| NO20060379L (no) | Den polymorfe form av 4-[6-acetyl-3-[3-(4-acetyl-3-hydroksy-2-propylfenyltio)propoksy]-2-propylfenoksybutansyre | |
| AR077416A2 (es) | Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos | |
| CO5280050A1 (es) | Desnaturalizantes para las sales aminas simpaticomimeticas | |
| DK0889877T3 (da) | Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer | |
| DK1206467T3 (da) | N-heterocykliske derivater som NOS-inhibitorer | |
| EA200200510A1 (ru) | 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр | |
| BRPI0412659A (pt) | isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto | |
| AR026102A1 (es) | Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion | |
| DK0726893T3 (da) | Hidtil ukendte 4-piperidinyl-substituerede lactamer som neurokinon 2-receptor-antagonister til behandling af astma | |
| DE602004011790D1 (de) | Meldoniumsalze, verfahren zu deren herstellung und auf ihnen basierende pharmazeutische zusammensetzung | |
| ES2169654B1 (es) | Agente desfoliante | |
| UY27410A1 (es) | Formas novedosas crudas cristalinas | |
| AR027360A1 (es) | Composicion farmaceutica | |
| AR009672A1 (es) | Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par | |
| AR030416A1 (es) | COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA | |
| CO4700300A1 (es) | Procedimiento para preparar olanzapina | |
| BR0109508A (pt) | Forma ii, cristalina, de cabergolina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |